Novavax COVID-19 vaccine shows 90% overall efficacy in Phase 3 trial

Author: Justin Low | Category: News

More good news in the vaccine space

The study also shows that the vaccine is 100% effective against moderate cases of COVID-19, while also protecting against variants. A key feature of the Novavax vaccine is that it is easy to store and transport, so that may help to bolster vaccine rollouts globally once supply is made available and if it is approved especially in developing countries.
Invest in yourself. See our forex education hub.

By continuing to browse our site you agree to our use of cookies, revised Privacy Notice and Terms of Service. More information about cookiesClose